1.
Perletti G. Reply to: Clarification to provide further understanding of the conduct and design of TROPIC: A Phase 3 trial of cabazitaxel versus mitoxantrone in patients with metastatic castration-resistant prostate cancer. AIUA [Internet]. 31Mar.2016 [cited 17Sep.2019];88(1):74-5. Available from: https://pagepressjournals.org/index.php/aiua/article/view/aiua.2016.1.74